Oncotherapeutics: Multiple Myeloma trials
The registry lists 22 Multiple Myeloma studies with Oncotherapeutics as lead sponsor. 5 are open to participants now and 4 have results posted.
Early Phase 1 1Phase 1 9Phase 2 15Phase 3 1No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Trial of Selinexor, Ruxolitinib and MethylprednisoloneRecruitingNCT06225310Phase 1
- Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple MyelomaRecruitingNCT06209606Early Phase 1
- A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple MyelomaRecruitingNCT06115135Phase 2
- Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.RecruitingNCT04519476Phase 1
- A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) PatientsRecruitingNCT03110822Phase 1
- Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing RegimensTerminatedNCT01695330Phase 2Results posted
- Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple MyelomaCompletedNCT01160484Phase 2Results posted
- A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple MyelomaCompletedNCT01160380Phase 3Results posted
- Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple MyelomaCompletedNCT00743288Phase 1/2Results posted
- Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM PatientsTerminatedNCT03733691Phase 2
- Combination Study for High Risk Multiple Myeloma PatientsTerminatedNCT03104270Phase 2
- Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 CarfilzomibTerminatedNCT02294357Phase 2
- Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma PatientsCompletedNCT02206425Phase 1/2
- Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma PatientsTerminatedNCT02188368Phase 2
- Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple MyelomaStatus unknownNCT01792102Phase 1/2
- Serum Vitamin D Levels and Peripheral Neuropathy Among Multiple Myeloma PatientsCompletedNCT01697839
- Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple MyelomaStatus unknownNCT01541332Phase 1/2
- Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing TreatmentsCompletedNCT01365559Phase 1/2
- Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple MyelomaStatus unknownNCT00742404Phase 2
- Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00317811Phase 2
- Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00316940Phase 1
- Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple MyelomaWithdrawnNCT00085345Phase 2